Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is a clinical-stage biotechnology company developing cell therapies for unmet medical needs.
It is working in the areas of eye disease, spinal cord injuries and cancer immuno-therapy.
With three clinical-stage assets, the $140 million market capitalization looks anomalous and suggests that Lineage is flying well below the radar.
Join us at 1pm EST on October 14 at our One2One virtual investor conference to learn more about this hidden gem of the world of life sciences.
About the event:
- Ours is an audience of astute high net worth investors, fund managers, private client brokers and analysts
- We look beyond the numbers and meet the people creating the value for shareholders
- Each company has a presentation slot followed by Q & A, giving you the chance to discover the real story
- You can watch the event afterwards on our YouTube channel